Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of Refractory Prurigo Nodularis With Lenalidomide

Treatment of Refractory Prurigo Nodularis With Lenalidomide THE CUTTING EDGE: CHALLENGES IN MEDICAL AND SURGICAL THERAPIES SECTION EDITOR: EDWARD W. COWEN, MD, MHSc; ASSISTANT SECTION EDITORS: MURAD ALAM, MD; RUTH ANN VLEUGELS, MD Treatment of Refractory Prurigo Nodularis With Lenalidomide Holly Kanavy, DO; Jennifer Bahner, MD; Neil J. Korman, MD, PhD; Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio Prurigo nodularis is an intensely pruritic disorder in which ter 18 months of therapy, which necessitated discon- chronic scratching and rubbing lead to the formation of tinuation of thalidomide. Other therapies used in- eroded and excoriated skin nodules that may become gen- cluded capsaicin cream, oral naltrexone (50 mg/d) for 2 eralized. Therapy for prurigo nodularis is notoriously dif- months, minocycline (100 mg twice daily) for 4 months, ficult, and relief of pruritus and clearing of the skin le- and gabapentin (600 mg 3 times daily) for 3 months, none sions is exceedingly difficult to achieve. of which led to any improvement. In addition, owing to the availability of sample medication, we treated her with a 12-week course of intramuscular alefacept (15 mg/ REPORT OF A CASE wk), a 12-week course of subcutaneous etanercept (50 mg twice weekly), and intralesional alefacept (10 mg/ A 45-year-old http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Treatment of Refractory Prurigo Nodularis With Lenalidomide

Kanavy, Holly; Bahner, Jennifer; Korman, Neil J.
JAMA Dermatology , Volume 148 (7) – Jul 1, 2012
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/treatment-of-refractory-prurigo-nodularis-with-lenalidomide-Rkkx4GSNPi

References (25)

Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archdermatol.2011.2918
pmid
22801610
Publisher site
See Article on Publisher Site

Abstract

THE CUTTING EDGE: CHALLENGES IN MEDICAL AND SURGICAL THERAPIES SECTION EDITOR: EDWARD W. COWEN, MD, MHSc; ASSISTANT SECTION EDITORS: MURAD ALAM, MD; RUTH ANN VLEUGELS, MD Treatment of Refractory Prurigo Nodularis With Lenalidomide Holly Kanavy, DO; Jennifer Bahner, MD; Neil J. Korman, MD, PhD; Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio Prurigo nodularis is an intensely pruritic disorder in which ter 18 months of therapy, which necessitated discon- chronic scratching and rubbing lead to the formation of tinuation of thalidomide. Other therapies used in- eroded and excoriated skin nodules that may become gen- cluded capsaicin cream, oral naltrexone (50 mg/d) for 2 eralized. Therapy for prurigo nodularis is notoriously dif- months, minocycline (100 mg twice daily) for 4 months, ficult, and relief of pruritus and clearing of the skin le- and gabapentin (600 mg 3 times daily) for 3 months, none sions is exceedingly difficult to achieve. of which led to any improvement. In addition, owing to the availability of sample medication, we treated her with a 12-week course of intramuscular alefacept (15 mg/ REPORT OF A CASE wk), a 12-week course of subcutaneous etanercept (50 mg twice weekly), and intralesional alefacept (10 mg/ A 45-year-old

Journal

JAMA Dermatology – American Medical Association

Published: Jul 1, 2012

There are no references for this article.